Effects of celecoxib and naproxen on renal function in the elderly

Andrew Whelton, Gerald Schulman, Carl Wallemark, Edward J. Drower, Peter C. Isakson, Kenneth M. Verburg, G. Steven Geis

Research output: Contribution to journalArticle

Abstract

Objective: To compare the effects of celecoxib, a cyclooxygenase 2- specific inhibitor, with the nonspecific cyclooxygenase 1 and 2 inhibitor naproxen on renal function in 29 healthy elderly subjects in a single-blind, randomized, crossover study. Methods: Subjects received either celecoxib, 200 mg twice daily, for 5 days followed by celecoxib, 400 mg twice daily, for the next 5 days, or they received naproxen, 500 mg twice daily, for 10 days. After a 7-day washout, subjects were crossed over to receive the other regimen. Results: After the first dose, the trend was for a greater decrease in glomerular filtration rate with naproxen (-5.31 mL/min per 1.73 m2) compared with celecoxib (-0.86 mL/min per 1.73 m2). The treatment difference became statistically significant on day 6 (-7.53 vs -1.11 mL/min per 1.73 m2 for naproxen and celecoxib, respectively; P=.004). Urinary prostaglandin E2 and 6-keto-prostaglandin F(1α) excretion was significantly reduced from baseline across the treatment interval with both celecoxib and naproxen (P≤.04). There were no significant differences in prostaglandin excretion between these 2 agents (P≥.07). Small, transient decreases (P2 and 6-keto-prostaglandin F(1α) excretion, appear to be similar to those of nonspecific cyclooxygenase inhibitors such as naproxen.

Original languageEnglish (US)
Pages (from-to)1465-1470
Number of pages6
JournalArchives of Internal Medicine
Volume160
Issue number10
StatePublished - May 22 2000

Fingerprint

Celecoxib
Naproxen
Kidney
Cyclooxygenase 2 Inhibitors
Prostaglandins F
Cyclooxygenase 1
Cyclooxygenase Inhibitors
Glomerular Filtration Rate
Dinoprostone
Cross-Over Studies
Prostaglandins
Healthy Volunteers

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Whelton, A., Schulman, G., Wallemark, C., Drower, E. J., Isakson, P. C., Verburg, K. M., & Geis, G. S. (2000). Effects of celecoxib and naproxen on renal function in the elderly. Archives of Internal Medicine, 160(10), 1465-1470.

Effects of celecoxib and naproxen on renal function in the elderly. / Whelton, Andrew; Schulman, Gerald; Wallemark, Carl; Drower, Edward J.; Isakson, Peter C.; Verburg, Kenneth M.; Geis, G. Steven.

In: Archives of Internal Medicine, Vol. 160, No. 10, 22.05.2000, p. 1465-1470.

Research output: Contribution to journalArticle

Whelton, A, Schulman, G, Wallemark, C, Drower, EJ, Isakson, PC, Verburg, KM & Geis, GS 2000, 'Effects of celecoxib and naproxen on renal function in the elderly', Archives of Internal Medicine, vol. 160, no. 10, pp. 1465-1470.
Whelton A, Schulman G, Wallemark C, Drower EJ, Isakson PC, Verburg KM et al. Effects of celecoxib and naproxen on renal function in the elderly. Archives of Internal Medicine. 2000 May 22;160(10):1465-1470.
Whelton, Andrew ; Schulman, Gerald ; Wallemark, Carl ; Drower, Edward J. ; Isakson, Peter C. ; Verburg, Kenneth M. ; Geis, G. Steven. / Effects of celecoxib and naproxen on renal function in the elderly. In: Archives of Internal Medicine. 2000 ; Vol. 160, No. 10. pp. 1465-1470.
@article{b6a740c799ff4be0bb991fbf0df41582,
title = "Effects of celecoxib and naproxen on renal function in the elderly",
abstract = "Objective: To compare the effects of celecoxib, a cyclooxygenase 2- specific inhibitor, with the nonspecific cyclooxygenase 1 and 2 inhibitor naproxen on renal function in 29 healthy elderly subjects in a single-blind, randomized, crossover study. Methods: Subjects received either celecoxib, 200 mg twice daily, for 5 days followed by celecoxib, 400 mg twice daily, for the next 5 days, or they received naproxen, 500 mg twice daily, for 10 days. After a 7-day washout, subjects were crossed over to receive the other regimen. Results: After the first dose, the trend was for a greater decrease in glomerular filtration rate with naproxen (-5.31 mL/min per 1.73 m2) compared with celecoxib (-0.86 mL/min per 1.73 m2). The treatment difference became statistically significant on day 6 (-7.53 vs -1.11 mL/min per 1.73 m2 for naproxen and celecoxib, respectively; P=.004). Urinary prostaglandin E2 and 6-keto-prostaglandin F(1α) excretion was significantly reduced from baseline across the treatment interval with both celecoxib and naproxen (P≤.04). There were no significant differences in prostaglandin excretion between these 2 agents (P≥.07). Small, transient decreases (P2 and 6-keto-prostaglandin F(1α) excretion, appear to be similar to those of nonspecific cyclooxygenase inhibitors such as naproxen.",
author = "Andrew Whelton and Gerald Schulman and Carl Wallemark and Drower, {Edward J.} and Isakson, {Peter C.} and Verburg, {Kenneth M.} and Geis, {G. Steven}",
year = "2000",
month = "5",
day = "22",
language = "English (US)",
volume = "160",
pages = "1465--1470",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Effects of celecoxib and naproxen on renal function in the elderly

AU - Whelton, Andrew

AU - Schulman, Gerald

AU - Wallemark, Carl

AU - Drower, Edward J.

AU - Isakson, Peter C.

AU - Verburg, Kenneth M.

AU - Geis, G. Steven

PY - 2000/5/22

Y1 - 2000/5/22

N2 - Objective: To compare the effects of celecoxib, a cyclooxygenase 2- specific inhibitor, with the nonspecific cyclooxygenase 1 and 2 inhibitor naproxen on renal function in 29 healthy elderly subjects in a single-blind, randomized, crossover study. Methods: Subjects received either celecoxib, 200 mg twice daily, for 5 days followed by celecoxib, 400 mg twice daily, for the next 5 days, or they received naproxen, 500 mg twice daily, for 10 days. After a 7-day washout, subjects were crossed over to receive the other regimen. Results: After the first dose, the trend was for a greater decrease in glomerular filtration rate with naproxen (-5.31 mL/min per 1.73 m2) compared with celecoxib (-0.86 mL/min per 1.73 m2). The treatment difference became statistically significant on day 6 (-7.53 vs -1.11 mL/min per 1.73 m2 for naproxen and celecoxib, respectively; P=.004). Urinary prostaglandin E2 and 6-keto-prostaglandin F(1α) excretion was significantly reduced from baseline across the treatment interval with both celecoxib and naproxen (P≤.04). There were no significant differences in prostaglandin excretion between these 2 agents (P≥.07). Small, transient decreases (P2 and 6-keto-prostaglandin F(1α) excretion, appear to be similar to those of nonspecific cyclooxygenase inhibitors such as naproxen.

AB - Objective: To compare the effects of celecoxib, a cyclooxygenase 2- specific inhibitor, with the nonspecific cyclooxygenase 1 and 2 inhibitor naproxen on renal function in 29 healthy elderly subjects in a single-blind, randomized, crossover study. Methods: Subjects received either celecoxib, 200 mg twice daily, for 5 days followed by celecoxib, 400 mg twice daily, for the next 5 days, or they received naproxen, 500 mg twice daily, for 10 days. After a 7-day washout, subjects were crossed over to receive the other regimen. Results: After the first dose, the trend was for a greater decrease in glomerular filtration rate with naproxen (-5.31 mL/min per 1.73 m2) compared with celecoxib (-0.86 mL/min per 1.73 m2). The treatment difference became statistically significant on day 6 (-7.53 vs -1.11 mL/min per 1.73 m2 for naproxen and celecoxib, respectively; P=.004). Urinary prostaglandin E2 and 6-keto-prostaglandin F(1α) excretion was significantly reduced from baseline across the treatment interval with both celecoxib and naproxen (P≤.04). There were no significant differences in prostaglandin excretion between these 2 agents (P≥.07). Small, transient decreases (P2 and 6-keto-prostaglandin F(1α) excretion, appear to be similar to those of nonspecific cyclooxygenase inhibitors such as naproxen.

UR - http://www.scopus.com/inward/record.url?scp=0034701938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034701938&partnerID=8YFLogxK

M3 - Article

C2 - 10826459

AN - SCOPUS:0034701938

VL - 160

SP - 1465

EP - 1470

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 10

ER -